NZ762860A - Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients - Google Patents

Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients

Info

Publication number
NZ762860A
NZ762860A NZ762860A NZ76286018A NZ762860A NZ 762860 A NZ762860 A NZ 762860A NZ 762860 A NZ762860 A NZ 762860A NZ 76286018 A NZ76286018 A NZ 76286018A NZ 762860 A NZ762860 A NZ 762860A
Authority
NZ
New Zealand
Prior art keywords
acid sphingomyelinase
treatment
deficiency patients
abnormal bone
sphingomyelinase deficiency
Prior art date
Application number
NZ762860A
Other languages
English (en)
Inventor
Ana Cristina Scheidt-Puga
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of NZ762860A publication Critical patent/NZ762860A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
NZ762860A 2017-08-24 2018-08-22 Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients NZ762860A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549732P 2017-08-24 2017-08-24
EP17306720 2017-12-07
PCT/IB2018/056346 WO2019038685A2 (en) 2017-08-24 2018-08-22 TREATMENT OF ABNORMAL BONE CONDITIONS IN PATIENTS WITH ACIDIC SPHINGOMYELASE DISEASE

Publications (1)

Publication Number Publication Date
NZ762860A true NZ762860A (en) 2025-09-26

Family

ID=63556374

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ762860A NZ762860A (en) 2017-08-24 2018-08-22 Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients

Country Status (17)

Country Link
US (2) US11898175B2 (enExample)
EP (1) EP3672622B1 (enExample)
JP (3) JP7216075B2 (enExample)
KR (2) KR20250025051A (enExample)
CN (2) CN118453843A (enExample)
AU (2) AU2018319565B2 (enExample)
BR (1) BR112020003541A2 (enExample)
CA (1) CA3073648A1 (enExample)
CO (1) CO2020001801A2 (enExample)
ES (1) ES2970423T3 (enExample)
IL (1) IL272757B2 (enExample)
MX (2) MX2020002106A (enExample)
NZ (1) NZ762860A (enExample)
PL (1) PL3672622T3 (enExample)
SG (1) SG11202001544VA (enExample)
TW (1) TWI791040B (enExample)
WO (1) WO2019038685A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
UY38238A (es) * 2018-05-25 2019-12-31 Genzyme Corp Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida
JP7568648B2 (ja) * 2019-05-31 2024-10-16 ジェンザイム・コーポレーション 二次元ｌｃ－ｍｓ／ｍｓシステム
CN112773779B (zh) * 2021-02-04 2022-08-16 上海交通大学医学院附属新华医院 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
CN1302897A (zh) 1999-10-28 2001-07-11 上海博容基因开发有限公司 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸
WO2006130769A2 (en) * 2005-06-02 2006-12-07 Tercica, Inc. Methods for treatment of growth disorders
KR102094253B1 (ko) * 2009-08-28 2020-03-31 이칸 스쿨 오브 메디슨 엣 마운트 시나이 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법
HK1207005A1 (en) 2012-03-02 2016-01-22 夏尔人类遗传性治疗公司 Compositions and methods for treating type iii gaucher disease
WO2014093354A1 (en) 2012-12-12 2014-06-19 Teva Pharmaceutical Industries Ltd. Fusion of human growth hormone and albumin, formulation and uses thereof
PL3004896T3 (pl) 2013-06-07 2020-04-30 Genzyme Corporation Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania

Also Published As

Publication number Publication date
MX2023010908A (es) 2023-09-27
AU2018319565A1 (en) 2020-04-09
KR20200044064A (ko) 2020-04-28
JP7216075B2 (ja) 2023-01-31
PL3672622T3 (pl) 2024-04-02
KR102769578B1 (ko) 2025-02-20
IL272757A (en) 2020-04-30
ES2970423T3 (es) 2024-05-28
IL272757B1 (en) 2024-03-01
TWI791040B (zh) 2023-02-01
SG11202001544VA (en) 2020-03-30
JP2023052459A (ja) 2023-04-11
BR112020003541A2 (pt) 2020-09-01
TW201919689A (zh) 2019-06-01
AU2018319565B2 (en) 2025-02-20
CN118453843A (zh) 2024-08-09
EP3672622B1 (en) 2023-11-08
WO2019038685A2 (en) 2019-02-28
CN111344003B (zh) 2024-05-07
CA3073648A1 (en) 2019-02-28
JP2024050732A (ja) 2024-04-10
JP7431356B2 (ja) 2024-02-14
KR20250025051A (ko) 2025-02-20
MX2020002106A (es) 2020-07-14
EP3672622A2 (en) 2020-07-01
IL272757B2 (en) 2024-07-01
WO2019038685A3 (en) 2019-05-02
US20210139868A1 (en) 2021-05-13
JP2020531527A (ja) 2020-11-05
CO2020001801A2 (es) 2020-04-01
US11898175B2 (en) 2024-02-13
CN111344003A (zh) 2020-06-26
RU2020111649A (ru) 2021-09-24
AU2025203384A1 (en) 2025-05-29
US20240218338A1 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
MX2023000051A (es) Metodos de acondicionamiento de pacientes para tratamiento con linfocitos t.
MX2025012429A (es) Composiciones y metodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano
NZ762860A (en) Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
JOP20200035A1 (ar) تركيبات حمض أميني لعلاج الإصابات العصبية
BR112019006918A2 (pt) proteínas actriib variantes e usos das mesmas
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
IN2014DN08676A (enExample)
PH12021551660A1 (en) Implant for bone
MX2018014279A (es) Tratamiento terapeutico de cancer de mama con base en estado de c-maf.
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
MX2020005182A (es) Tratamiento terapeutico del cancer de mama basado en el estado del c-maf.
PH12017501070B1 (en) Peptides and their use in the treatment of skin
MX2020007586A (es) Proceso de fabricacion de moduladores de somatostatina.
MY185691A (en) An asseointegrable device
AU2018236629A8 (en) Hydrogel patch
MX370570B (es) Marcador para trastornos de la esfingomielinasa acida y sus usos.
MX2016014569A (es) Metodos y dispositivos para conectar o reconectar tejido blando al hueso.
ZA202004002B (en) Pharmaceutical composition
TW201613569A (en) Composition consisting of kukoamine A and/or kukoamine B and method of using thereof
MX2020013684A (es) Formulaciones/composiciones que comprenden ibrutinib.
PT3672622T (pt) Esfingomielinase ácida humana recombinante para utlização no tratamento de condições ósseas anormais em pacientes com deficiência de esfingomielinase ácida
Yikilmaz et al. Vitamin B12 level have prognostic significance in multiple myeloma patients
GB2567398A (en) Method and composition for treating dysbiosis and related disease states
EP3154444A4 (en) Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
TR201800560A2 (tr) Görüntülü muayene ve terapide kullanılan bir sistem.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: GENZYME CORPORATION, US

Effective date: 20230615